Login / Signup

Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.

Nigel P MurrayRicardo VillalonDan HartmannPatricia Maria RodriguezSocrates Aedo
Published in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2021)
Following chemotherapy, improvements in immune function were associated with improved MRD subtype and a better relapse-free survival.
Keyphrases
  • free survival
  • locally advanced
  • oxidative stress
  • squamous cell carcinoma
  • metastatic colorectal cancer